Elisa Oricchio (born 1979) is an Italian cancer researcher and Associate Professor at École Polytechnique Fédérale de Lausanne.

She discovered that EphA7 activates the tumor suppressor gene for patients with follicular lymphoma and was awarded the Lorini Foundation Award and Blavatnik Award for Young Scientists for her discovery. She was appointed Institute Director of ISREC in October 2022.

Slavica Dimitrieva works as an Associate Director & Senior Principal Scientist at the Oncology Data Science department at the Novartis Institutes for BioMedical Research in Basel. She is passionate about applying AI on multi-modal data for oncology drug discovery and precision medicine.

Slavica has a background in Computer Science and a PhD in Computational Biology from the EPFL in Lausanne. During her studies, she received an ETH Medal for her Master thesis at ETH Zurich, and later a Best Graduate Paper Award by the Swiss Institute of Bioinformatics. After a postdoc at the Imperial College in London, she worked as a Bioinformatics expert and Lecturer at the Functional Genomics Centre in Zurich, before joining Novartis. At Novartis her focus is on data-driven drug discovery, and she co-leads the data science efforts in target identification.

Prof. Olivier Michielin obtained a Masters of Physics in 1991 at the Swiss Federal Institute of Technology and a Medical Degree from the University of Lausanne in 1997.

He pursued his PhD training under the supervision of Jean-Charles Cerottini (Ludwig Institute) and Martin Karplus (Harvard and Strasbourg Universities, Chemistry Nobel Prize Laureate 2013). He was appointed Group Leader of the Swiss Institute of Bioinformatics in 2002 and became an Assistant Professor and Privat Docent at the Medical Faculty of Lausanne in 2004 and 2005, respectively. In parallel, he has trained as a medical oncologist and obtained his board certification in 2007 at the Department of oncology of the Lausanne University Hospital (CHUV) where he is currently heading the melanoma clinic. He was appointed Associate Professor in 2010 and full Professor in 2019. Prof. Olivier Michielin is mainly focused on translational oncology, developing new molecularly defined therapeutic approaches based on original bioinformatics techniques developed in his laboratory, as well as melanoma clinical trials at the Lausanne University Hospital. In 2016, Prof. Olivier Michielin was appointed Head of the Center for Precision Oncology within the Department of oncology from the CHUV and in October 2022 Head of the Department of Oncology of the HUG.

Jean Hausser is principal investigator at Karolinska Institute and SciLifeLab, Sweden.

Following a PhD in bioinformatics (2010, Uni Basel), he performed research on optimality theory of gene regulation (Weizmann Institute, Israel) and on the single-cell dynamics of the tumor micro-environment (Uni Lausanne). With his team, he researches how cancer cells escape the immune system by combining experiments, data science and mathematical theory. He authored 34 publications which have been cited over 9000 times.

Dr. Dubuis brings nearly 20 years of international experience in the field of life sciences, both in industry and in research institutes.

He has held various management positions in pharmaceutical companies such as Chemap, Ciba-Geigy/Novartis and Lonza. Benoit joined EPFL (Ecole Polytechnique Fédérale de Lausanne) in 2000, as Director of Licenses and advisor to the school's management. He established the School of Life Sciences and served as its first Dean. He also launched the BioAlps association and founded ExcellGene SA. In 2004, he co-founded Eclosion, the first Swiss seed fund and incubator for life sciences, of which he is director. Aiming to transform the strong regional potential for innovation in life sciences into economic value and employment, Eclosion offers researchers a full range of managerial and scientific support for their projects, from funding to validation resources (www.outbreak.com).

Dr María Rodrίguez Martίnez is the Technical Leader of Systems Biology at IBM Research Europe (Switzerland) and an associated member of the Department of Biology at ETH since 2014. Originally trained as a physicist, she became interested in computational biology during her postdoctoral training at the Weizmann Institute of Science (Israel). Her research focuses on understanding cancer dysregulation mechanisms to develop computational approaches for cancer personalized medicine. To support this area of research, she has led two large EU-funded consortia focused on prostate cancer and pediatric cancers.

As a computational biologist, her research lies at the intersection of mechanistic and artificial intelligence models, with a strong interest in developing interpretable deep learning approaches. Her team has developed interpretable approaches for analysing single-cell and drug sensitivity data. More recently, she is interested in modelling the interaction between cancer and the immune responses to investigate cancer immunotherapies.